{
    "nctId": "NCT02115984",
    "briefTitle": "Study of the Safety and Leukostimulatory Activity of the Preparation \"Panagen\" in Patients With Breast Cancer",
    "officialTitle": "Double-blind Multicenter Placebo-controlled Study of the Safety and Leukostimulatory Activity of the Preparation \"Panagen\" in Patients With Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 80,
    "primaryOutcomeMeasure": "The Quantity of Leukocytes and Neutrophils in the Blood of Patients",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Signed and dated written informed consent\n* Women at an age of \u226518 years\n* Stage II-IV breast cancer (with distant metastases)\n* The patients will be subject to chemotherapy with cyclophosphan/doxorubicin/ fluorouracil as a standard chemotherapy for treating breast cancer\n* The patients have not been earlier subject to chemotherapy\n* Functional status according to the Eastern Cooperative Oncology Group (ECOG) \u22642\n* Leukocyte counts of \u22653 \u00d7 109/L before the treatment course\n* Neutrophil counts of \u22651.5 \u00d7 109/L before the treatment course\n* Platelet counts of \u2265100 \u00d7 109/L before the treatment course\n* Adequate heart function\n* Adequate liver function, that is, alanine aminotransferase / aspartate aminotransferase (ALT / AST) activity \\< 2.5 \u00d7 upper limit of normal (ULN); acid phosphatase activity \\< 5 \u00d7 ULN; and bilirubin concentration \\< 5 \u00d7 ULN; and\n* Adequate renal function, that is, the creatinine concentration in the blood serum \\< 1.5 \u00d7 ULN; urea concentration \\< ULN; and endogenous creatinine clearance\n\nExclusion Criteria:\n\n* Participation in clinical trials less than 30 days before sequential randomization\n* Previous exposure to Panagen or any other leukostimulatory drugs at a stage of clinical development\n* Known hypersensitivity to cyclophosphan, doxorubicin, or fluorouracil\n* Therapy with systemically active antibiotics less than 72 h before the beginning of chemotherapy\n* Long-term oral intake of corticosteroids\n* Previous X-ray therapy performed less than 4 weeks before randomization\n* Previous transplantation of hematopoietic stem cells\n* Other malignant neoplasms during the last 5 years except for basal cell or flat cell carcinoma or intraepithelial carcinoma of the uterine cervix\n* Any disease or state that according to the opinion of researcher can influence patient's safety or the estimation of a final trial point; and\n* Pregnant and nursing women; the fertile patients should use chemical or barrier contraceptives during the period of trials",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}